Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Rongxin ^a   Liu, Shu ^b   Ye, Huijing ^a   Li, Jiali ^c   Du, Yi ^d   Chen, Lingyan ^e   Liu, Xiaoman ^c   Ding, Yungang ^a   Li, Qian ^a   Mao, Yuxiang ^a   Ai, Siming ^a   Zhang, Ping ^a   Ma, Wenfang ^a   Yang, Huasheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN MDM2; PROTEIN P53;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; PROPORTIONAL HAZARDS MODEL; RETINOBLASTOMA; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939865181     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13300     Document Type: Article

References (57)

1. Dimaras, H. et al. Retinoblastoma. Lancet 379, 1436-1446 (2012). doi: 10.1016/S0140-6736(11)61137-9.
2. Kivelä, T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br. J. Ophthalmol. 93, 1129-1131 (2009). doi: 10.1136/bjo.2008.150292.
3. Conkrite, K. et al. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 25, 1734-1745 (2011). doi: 10.1101/gad.17027411.
4. Gartel, A. L. & Radhakrishnan, S. K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65, 3980-3985 (2005). doi: 10.1158/0008-5472.CAN-04-3995.
5. Perry, M. E. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect. Biol. 2, a000968 (2010). doi: 10.1101/cshperspect.a000968.
6. Corson, T. W. & Gallie, B. L. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46, 617-634 (2007). doi: 10.1002/gcc.20457.
7. Chakraborty, S. et al. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 90, 344-353 (2007). doi: 10.1016/j.ygeno.2007.05.002.
8. Reis, A. H., Vargas, F. R. & Lemos, B. More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front. Genet. 3, 284 (2012). doi: 10.3389/fgene.2012.00284.
9. Castéra, L. et al. MDM2 as a modifier gene in retinoblastoma. J. Natl Cancer Inst. 102, 1805-1808 (2010). doi: 10.1093/jnci/ djq416.
10. Epistolato, M. C. et al. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma. J. Hum. Genet. 56, 685-686 (2011). doi: 10.1038/jhg.2011.82.
11. de Oliveira Reis, A. H. et al. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr. Blood Cancer 59, 39-43 (2012). doi: 10.1002/pbc.24014.
12. McEvoy, J. et al. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLOS ONE 7, e42739 (2012). doi: 10.1371/journal.pone.0042739.
13. Carvalho, I. N., Reis, A. H., Cabello, P. H. & Vargas, F. R. Polymorphisms of CDKN1A gene and risk of retinoblastoma. Carcinog. 34, 2774-2777 (2013). doi: 10.1093/carcin/bgt308.
14. Dumont, P., Leu, J. I., Della Pietra, A. C., George, D. L. & Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365 (2003). doi: 10.1038/ng1093.
15. Sullivan, A. & Lu, X. ASPP: a new family of oncogenes and tumour suppressor genes. Br. J. Cancer 96, 196-200 (2007). doi: 10.1038/sj.bjc.6603525.
16. Furihata, M. et al. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res. 8, 1192-1195 (2002).
17. Schneider-Stock, R. et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am. J. Pathol. 164, 1233-1241 (2004). doi: 10.1016/S0002-9440(10)63211-7.
18. Pérez, L. O., Abba, M. C., Dulout, F. N. & Golijow, C. D. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J. Gastroenterol. 12, 1426-1429 (2006).
19. Zhu, Z. Z. et al. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J. Zhejiang Univ. Sci. B 9, 847-852 (2008). doi: 10.1631/jzus.B0820100.
20. Chen, W. C. et al. Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol. Res. 28, 293-296 (2000). doi: 10.1007/s002400000117.
21. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004). doi: 10.1016/j.cell.2004.11.022.
22. Rayburn, E., Zhang, R., He, J. & Wang, H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets. 5, 27-41 (2005). doi: 10.2174/1568009053332636.
23. Sun, Y. F., Leu, J. D., Chen, S. M., Lin, I. F. & Lee, Y. J. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9, 13 (2009). doi: 10.1186/1471-2407-9-13.
24. Li, G. et al. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27, 2028-2033 (2006). doi: 10.1093/carcin/bgl047.
25. Heist, R. S. et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J. Clin. Oncol. 25, 2243-2247 (2007). doi: 10.1200/JCO.2006.08.8914.
26. Paulin, F. E. et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8, 281 (2008). doi: 10.1186/1471-2407-8-281.
27. Broude, E. V. et al. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 6, 1468-1471 (2007). doi: 10.4161/ cc.6.12.4313.
28. Zhang, Z. et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000-16006 (2004). doi: 10.1074/jbc.M312264200.
29. Mousses, S. et al. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet. 4, 1089-1092 (1995). doi: 10.1093/hmg/4.6.1089.
30. Johnson, G. G. et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res. 69, 5210-5217 (2009). doi: 10.1158/0008-5472.CAN-09-0627.
31. Liu, F. et al. P21 codon 31 polymorphism associated with cancer among white people: evidence from a meta-analysis involving 78, 074 subjects. Mutagenesis 26, 513-521 (2011). doi: 10.1093/mutage/ger010.
32. Xu, X. L. et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137, 1018-1031 (2009). doi: 10.1016/j.cell.2009.03.051.
33. Whibley, C., Pharoah, P. D. & Hollstein, M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95-107 (2009). doi: 10.1038/nrc2584.
34. Chung, S. E. et al. Clinical manifestations and treatment of retinoblastoma in Korea. Br. J. Ophthalmol. 92, 1180-1184 (2008). doi: 10.1136/bjo.2008.140046.
35. Chang, C. Y. et al. Retinoblastoma in Taiwan: survival rate and prognostic factors. Jpn. J. Ophthalmol. 50, 242-249 (2006). doi: 10.1007/s10384-005-0320-y.
36. Zhao, J., Li, S., Shi, J. & Wang, N. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br. J. Ophthalmol. 95, 1372-1375 (2011). doi: 10.1136/bjo.2010.191130.
37. Kashyap, S. et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr. Blood Cancer 58, 356-361 (2012). doi: 10.1002/pbc.23239.
38. Zhao, J. et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J. Clin. Oncol. 29, 845-851 (2011). doi: 10.1200/JCO.2010.32.5332.
39. Savas, S., Liu, G. & Xu, W. Special considerations in prognostic research in cancer involving genetic polymorphisms. BMC Med. 11, 149 (2013). doi: 10.1186/1741-7015-11-149.
40. Dean, M., Carrington, M. & O'Brien, S. J. Balanced polymorphism selected by genetic versus infectious human disease. Annu. Rev. Genomics Hum. Genet. 3, 263-292 (2002). doi: 10.1146/annurev.genom.3.022502.103149.
41. Hartwig, F. P. et al. Evidence for an epistatic effect between TP53 R72P and MDM2 T309G SNPs in HIV infection: a crosssectional study in women from South Brazil. PLOS ONE 9, e89489 (2014). doi: 10.1371/journal.pone.0089489.
42. Saadatian, Z. et al. Association of rs1219648 in FGFR2 and rs1042522 in TP53 with premenopausal breast cancer in an Iranian Azeri population. Asian Pac. J. Cancer Prev. 15, 7955-7958 (2014). doi: 10.7314/APJCP.2014.15.18.7955.
43. Ramalho, E. A. et al. Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carcinoma in northeast Brazil. Biol. Res. 47, 3 (2014). doi: 10.1186/0717-6287-47-3.
44. Weige, C. C. et al. Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol. Cancer Res. 12, 1029-1041 (2014). doi: 10.1158/1541-7786.MCR-13-0286-T.
45. Rebbani, K. et al. TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol. Cancer 14, 74 (2015). doi: 10.1186/s12943-015-0340-2.
46. Kato, M. V. et al. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett. 106, 75-82 (1996). doi: 10.1016/0304-3835(96)04305-4.
47. Polsky, D. et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J. Natl Cancer Inst. 94, 1803-1806 (2002). doi: 10.1093/jnci/94.23.1803.
48. Giordana, M. T. et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro-oncology. 4, 115-122 (2002).
49. Haitel, A., Wiener, H. G., Baethge, U., Marberger, M. & Susani, M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 6, 1840-1844 (2000).
50. Ranuncolo, S. M. et al. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J. Neurooncol. 68, 113-121 (2004). doi: 10.1023/B:NEON.0000027741.19213.99.
51. Hu, Z. et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol. Biomarkers Prev. 16, 2717-2723 (2007). doi: 10.1158/1055-9965.EPI-07-0634.
52. Su, L. et al. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer 40, 259-266 (2003). doi: 10.1016/S0169-5002(03)00081-3.
53. Birgander, R. et al. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum. Hered. 46, 148-154 (1996). doi: 10.1159/000154344.
54. Kiss, S., Leiderman, Y. I. & Mukai, S. Diagnosis, classification, and treatment of retinoblastoma. Int. Ophthalmol. Clin. 48, 135-147 (2008). doi: 10.1097/IIO.0b013e3181693670.
55. Chawla, B. et al. Correlation between clinical features, magnetic resonance imaging, and histopathologic findings in retinoblastoma: a prospective study. Ophthalmology 119, 850-856 (2012). doi: 10.1016/j.ophtha.2011.09.037.
56. Finger, P. T. et al. Retinoblastoma in AJCC Cancer Staging Manual (ed. Edge, S. et al.) 561-568 (Springer Science and Business Media, 2010).
57. Loparev, V., Cartas, M., Monken, C., Velpandi, A. & Srinivasan, A. An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J. Virol. Methods 34(1), 105-112 (1991). doi: 10.1016/0166-0934(91)90126-K.